Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sandoz Buys Rights To Pfizer Biosimilar
by Ann M. Thayer
February 22, 2016
| A version of this story appeared in
Volume 94, Issue 8
Sandoz, the generic drug arm of Novartis, has acquired rights to Pfizer’s biosimilar version of infliximab in 28 European countries. In 2015, Remicade, the brand-name version of the biologic, racked up $6.6 billion in sales for Johnson & Johnson. Infliximab is a TNF-α inhibitor used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. Sandoz must still complete Phase III clinical development and file for European regulatory approval of the biosimilar. Pfizer had to divest the program to win regulatory approval for its acquisition of Hospira.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X